Online inquiry

IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12936MR)

This product GTTS-WQ12936MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12936MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2581MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ3907MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ13772MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ1097MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ15956MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ13188MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ4436MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ8940MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW